Instituto Valenciano de Infertilidad, Valencia, Spain.
Fertil Steril. 2011 Mar 1;95(3):1031-6. doi: 10.1016/j.fertnstert.2010.10.021. Epub 2010 Nov 10.
To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists.
Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared.
University-affiliated private infertility clinic.
PATIENT(S): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle.
INTERVENTION(S): Recombinant LH administration since stimulation day 1.
MAIN OUTCOME MEASURE(S): Implantation rate, ongoing pregnancy rate.
RESULT(S): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% confidence interval [CI] 0.73-1.47), as was the ongoing pregnancy rate per started cycle: 37.4% versus 37.4%, OR 1.0 (95% CI 0.66-1.52). In older patients, the implantation rate was significantly higher in the rFSH + rLH group: 26.7% versus 18.6%, OR 1.56 (95% CI 1.04-2.33). Ongoing pregnancy rates per started cycle were 33.5% versus 25.3%, OR 1.49 (95% CI 0.93-2.38).
CONCLUSION(S): Recombinant LH administration significantly increased the implantation rate in patients aged 36 to 39 years. A clinically relevant better ongoing pregnancy rate per started cycle was observed, although the difference was not statistically significant. Patients younger than 36 years do not obtain any benefit from rLH administration.
分析黄体生成素（LH）给药对 GnRH 拮抗剂卵巢刺激周期结局的影响。
在两个年龄亚组中进行的随机、开放标签、对照试验。比较重组（r）FSH 与 rFSH+rLH 给药。
大学附属私立不孕诊所。
年龄在 35 岁以下（n=380）和 36 岁至 39 岁（n=340），接受首次或第二次 IVF 周期。
从刺激第 1 天开始给予重组 LH。
种植率、持续妊娠率。
在年轻人群中，种植率相似：27.8%对 28.6%，优势比（OR）为 1.03（95%置信区间[CI]为 0.73-1.47），每个开始周期的持续妊娠率也相似：37.4%对 37.4%，OR 为 1.0（95%CI 为 0.66-1.52）。在年龄较大的患者中，rFSH+rLH 组的种植率显著较高：26.7%对 18.6%，OR 为 1.56（95%CI 为 1.04-2.33）。每个开始周期的持续妊娠率为 33.5%对 25.3%，OR 为 1.49（95%CI 为 0.93-2.38）。
rLH 给药可显著提高 36-39 岁患者的种植率。观察到每个开始周期的持续妊娠率有临床相关的改善，尽管差异无统计学意义。年龄小于 36 岁的患者不能从 rLH 给药中获益。
